Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
news

Potential antibiotic alternative discovered within bacteria

A study has revealed an enzyme in bacteria that produces a molecule which is toxic to other bacteria and shows promise as an antibiotic substitute.

Researchers have found a new bacteria-killing toxin that shows promise in fighting superbug infectious diseases and could be an alternative to antibiotics.

The study was conducted at McMaster University, Canada, in collaboration with the Massachusetts Institute of Technology (MIT), US.

The team revealed that bacteria contain an enzyme which produces a growth-inhibiting toxin that is injected into rival bacteria to gain a competitive advantage. They discovered this while investigating how bacteria secrete antibacterial molecules.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

…the rapid production of (p)ppApp by this enzyme toxin depletes cells of a molecule called ATP”

The team determined the molecular structure of this toxin and found it resembles enzymes that synthesise a well-known bacterial signalling molecule called (p)ppGpp. This usually helps bacteria survive under stressful conditions, such as exposure to antibiotics.

“The three-dimensional (3D) structure of this toxin was at first puzzling because no known toxins look like enzymes that make (p)ppGpp and (p)ppGpp itself is not a toxin,” said researcher Shehryar Ahmad.

Suspecting the toxin might kill bacteria by overproducing harmful quantities of (p)ppGpp, the team examined the activity of the newly discovered enzyme. Rather than making (p)ppGpp, the enzyme instead produced a poorly understood but related molecule called (p)ppApp. Somehow, the production of (p)ppApp was harmful to bacteria.

The researchers determined that the rapid production of (p)ppApp by this enzyme toxin depletes cells of a molecule called ATP. When the supply of ATP is exhausted, essential cellular processes are compromised and the bacteria die.

Antibiotics with novel mechanism of action discovered

“I find it absolutely fascinating that evolution has essentially ‘repurposed’ an enzyme that normally helps bacteria survive antibiotic treatment and instead, has deployed it for use as an antibacterial weapon,” said co-senior author assistant professor John Whitney.

According to the researchers, their discovery could prove to be an alternative to antibiotics and reduce antimicrobial resistance.

The findings were published in Nature.